163 related articles for article (PubMed ID: 30954399)
1. Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience.
Xu MJ; Chen KS; Chang AJ; Lazar A; Shinohara K; Cunha JAM; Hsu IC
Brachytherapy; 2019; 18(4):470-476. PubMed ID: 30954399
[TBL] [Abstract][Full Text] [Related]
2. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
3. Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.
Raleigh DR; Chang AJ; Tomlin B; Cunha JA; Braunstein SE; Shinohara K; Gottschalk AR; Roach M; Hsu IC
Brachytherapy; 2015; 14(6):795-800. PubMed ID: 26198421
[TBL] [Abstract][Full Text] [Related]
4. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.
Yoshioka Y; Suzuki O; Isohashi F; Seo Y; Okubo H; Yamaguchi H; Oda M; Otani Y; Sumida I; Uemura M; Fujita K; Nagahara A; Ujike T; Kawashima A; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):675-82. PubMed ID: 26238951
[TBL] [Abstract][Full Text] [Related]
5. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
7. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
8. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2018 Nov; 129(2):370-376. PubMed ID: 30190166
[TBL] [Abstract][Full Text] [Related]
12. High-dose-rate brachytherapy as a monotherapy for prostate cancer--Single-institution results of the extreme fractionation regimen.
Kukiełka AM; Dąbrowski T; Walasek T; Olchawa A; Kudzia R; Dybek D
Brachytherapy; 2015; 14(3):359-65. PubMed ID: 25736733
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for prostate glands >60 cc treated with low-dose-rate brachytherapy.
Pham YD; Kittel JA; Reddy CA; Ciezki JP; Klein EA; Stephans KL; Tendulkar RD
Brachytherapy; 2016; 15(2):163-8. PubMed ID: 26796717
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
16. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: Toxicity and 6-year biochemical results.
Prada PJ; Ferri M; Cardenal J; Blanco AG; Anchuelo J; Díaz de Cerio I; Vázquez A; Pacheco M; Raba I; Ruiz S
Brachytherapy; 2018; 17(6):845-851. PubMed ID: 30030111
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
[TBL] [Abstract][Full Text] [Related]
18. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.
Cury FL; Duclos M; Aprikian A; Patrocinio H; Kassouf W; Shenouda G; Faria S; David M; Souhami L
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1417-23. PubMed ID: 21784585
[TBL] [Abstract][Full Text] [Related]
19. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]